Clinical trials: Fibroblast Activation Protein Inhibitor
Advanced Chronic Liver Disease, Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.
- Trial name
- NCT06974565
- Testing
- AZD2389, Quinidine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors
Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent/metastatic disease.
- Trial name
- LIFE (NCT06107608)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 58 people
- Sponsor
- Jules Bordet Institute
Pancreatic Ductal Adenocarcinoma (PDAC)
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed pancreatic ductal…
- Trial name
- FAPI-PRO (NCT07217717)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- SOFIE
Medullary Thyroid Cancer, Prositron Emission Tomography
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid…
- Conditions
- Medullary Thyroid Cancer, Prositron Emission Tomography, Fibroblast Activation Protein Inhibitor, Surgery
- Trial name
- NCT06277180
- Testing
- Surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharyngeal Cancer
68Ga-FAPI-46 PET/CT for the Prediction of Clinical Response to Neoadjuvant Therapy in Nasopharyngeal Carcinoma Patients
The goal of this clinical trial is to learn about the prediction of clinical response to neoadjuvant therapy in nasopharyngeal carcinoma patients via 68Ga-FAPI-46 PET/CT.
- Trial name
- NCT07139054
- Where
- China
- Volunteers
- 31 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Endometriosis
The Role of FAPI PET-CT in Diagnosing Endometriosis
Patients with suspected endometriosis scheduled for surgery will be identified. They will be asked to participate in a study evaluating the feasibility of FAPI PET-CT in diagnosing endometriosis.
- Trial name
- NCT06792318
- Testing
- FAPI PET-CT
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Ziv Hospital
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC.
- Trial name
- FAPI-46 PDAC (NCT05262855)
- Testing
- [68Ga]FAPI-46
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- SOFIE
Ovarian Cancer
[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
Fifty (n=50) patients with newly diagnosed ovarian cancer will undergo FAPI PET/CTs in addition to routine diagnostic workup (including FDG PET/CT) at primary staging and restaging.
- Trial name
- NCT05903807
- Testing
- 68Ga-FAPi-46
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Aalborg University Hospital
Malignant Tumor, Positron Emission Tomography
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
Adding targeted covalent radiopharmaceutical (TCR) moiety to fibroblast activation protein inhibitor (FAPI) can increase tumor uptake and tumor retention in pre-clinical studies.
- Conditions
- Malignant Tumor, Positron Emission Tomography, Fibroblast Activation Protein Inhibitor
- Trial name
- NCT06084767
- Testing
- 68Ga-TCR-FAPI PET/CT
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants
The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.
- Trial name
- NCT06846528
- Testing
- AZD2389, Itraconazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Tumor, Solid
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
To evaluate the potential usefulness of 68Ga-DOTA-F2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.
- Trial name
- NCT05637034
- Testing
- 68Ga-DOTA-F2 PET/CT and 18F-FDG
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types.
- Conditions
- Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT06503146
- Testing
- [18F]FAPI-74, [18F]FDG
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumor
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
This early phase I trial determines where and to what degree the tracer [68Ga] Ga-FAPI-04 accumulates in normal and cancer tissues in patients with high grade neuroendocrine cancer.
- Trial name
- NCT07132645
- Testing
- Computed Tomography, Gallium Ga 68-DOTA-FAPI-04, Positron Emission Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cholangiocarcinoma
The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Background Bile duct cancer (cholangiocarcinoma) represents the second most common type of hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually.
- Trial name
- FAPIChol (NCT06355427)
- Testing
- [18F]F-FAPI PET-CT
- Where
- 3 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Mara Veenstra, MD
Breast Neoplasms, Positron Emission Tomography
Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma
The aim of this study is to compare the diagnostic performance of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT in primary and metastatic lesions of breast cancer and to reveal the best diagnostic imaging time of 68Ga-FAPI-46 PET/CT.
- Conditions
- Breast Neoplasms, Positron Emission Tomography, Fibroblast Activation Protein Inhibitor, Fluorodeoxyglucose F18
- Trial name
- NCT05339113
- Testing
- 68Ga-FAPI-46 PET/CT
- Where
- Azerbaijan
- Volunteers
- 100 people
- Sponsor
- The National Center of Oncology, Azerbaijan
Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
The goal of this prospective observational study is to evaluate whether Gallium-68 Fibroblast Activation Protein Inhibitor (FAPI) PET/CT can improve detection, staging, and recurrence assessment in adult patients (≥18 years) with…
- Trial name
- FAPi-2 (NCT07337850)
- Testing
- gallium-68-Fibroblast Activation Protein Inhibitor
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Centre
Esophageal Cancer, Gastric Cancer (GC)
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric…
- Conditions
- Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- Trial name
- FAPI-GO (NCT07217704)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- SOFIE
Chronic Total Occlusion (CTO), Chronic Coronary Syndrome
FAPI Imaging Predicts Adverse Cardiac Events in Chronic Total Occlusion
Prospective, observational, single-center cohort study Hypothesis Higher myocardial FAPI uptake in CTO patients predicts a greater incidence of major adverse cardiovascular events (MACE) within 12 months after PCI.
- Trial name
- FACT-2 (NCT07020858)
- Testing
- FAPl lmaging
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Lin Zhao
Tuberculosis, Pulmonary
18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive biomarker to assess post-tuberculosis (post-TB) lung…
- Trial name
- NCT07077213
- Testing
- 18F-FAPI-74
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Fibroblast Activation Protein Inhibitor, PET/CT
68Ga-FAPI PET/CT in Malignant Tumors
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms.
- Conditions
- Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm
- Trial name
- NCT05034146
- Testing
- 68Ga-FAPI, PET/CT
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital